The IMDC (International Metastatic RCC Database Consortium) Risk Score for RCC predicts survival patients in metastatic renal cell carcinoma treated with systemic therapy.

Official website of the International mRCC Database Consortium (IMDC), including an up-to-date IMDC Prognosis Risk Calculator (IMDC Criteria / Heng Criteria) in addition to all past and present research fellows, publications, presentations and participating global institutions.

About IMDC Risk Categories: 75 – 80% of patients selecting 1st line mRCC treatment options have at least 1 of these risk factors, therefore classifying their mRCC

The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk criteria are currently the gold standard for predicting survival in patients with renal cell cancer (RCC) 5, 6. This method includes six risk factors: time from RCC diagnosis to first‐line systemic therapy <1 year, elevated platelet count, elevated absolute ...

2023年7月1日 · A retrospective analysis was conducted using the IMDC database to identify patients with mRCC treated with first-line IPI-NIVO, IO-VEGF, or VEGF-TT from 2002 to 2021 with available IMDC criteria. The IMDC database (www.imdconline.com) includes 13 056 consecutive patients treated at 40 international centers with a data cutoff of January 1, 2022 ...

We sought to validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in patients with metastatic renal cell carcinoma receiving next-line targeted therapy after progression on first-line targeted therapy.

2021年3月2日 · Background: The IMDC criteria have been used as a prognostic tool for patients with mRCC receiving single agent VEGF-targeted drugs, and more recently combination immuno-oncology (IO) +/- VEGF-targeted agents, which improve outcomes over VEGF TKI monotherapy. We sought to identify a subset of patients with very favorable outcomes, for which ...

Nowadays, most metastatic renal cell carcinoma (mRCC) patients are candidates for immunotherapy. Risk stratification is based on the IMDC model that was developed in an earlier era of vascular endothelial growth factor receptor inhibitors (VEGFRi). An updated, more accurate model is needed.

The International Metastatic Renal-Cell Carcinoma Database Consortium’s (IMDC) prognostic model to predict survival of metastatic kidney cancer patients has become the standard model used in clinical trials to categorize patients into favorable, intermediate, and poor risk.

IMDC Risk Model for Metastatic Renal Cell Carcinoma Predicts survival in patients with metastatic renal cell carcinoma treated with systemic therapy (also known as Heng criteria). <1 year from time of diagnosis to systemic therapy